SFU
SAGE

Stonehage Fleming (UK)’s Sage Therapeutics SAGE Stock Holding History

Stonehage Fleming (UK)’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-435
Closed -$16K – 252
2014
Q4 		$16K Buy
+435
New +$16.2K 0.01% 269

Other funds holding SAGE

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Stonehage Fleming (UK)'s SAGE Position: Q1 2015 in Review

Stonehage Fleming (UK) sold out of Sage Therapeutics (SAGE) in Q1 2015, closing a stake of 435 shares — an estimated $16K sold.

Stonehage Fleming (UK) first reported a position in SAGE in Q4 2014 and held it in 1 quarter. The position peaked at $16K in Q4 2014. 92 funds tracked by Wall St. Rank hold SAGE as of Q1 2015.

  • Stonehage Fleming (UK) reported no remaining Sage Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Stonehage Fleming (UK) sold 435 Sage Therapeutics shares in Q1 2015, an estimated $16K.
  • Stonehage Fleming (UK) first reported a position in Sage Therapeutics in Q4 2014 and held it in 1 quarter.
  • Stonehage Fleming (UK)'s Sage Therapeutics position peaked at $16K in Q4 2014.
  • 92 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2015.

Based on Stonehage Fleming (UK)'s 13F filing for Q1 2015, filed 11 Oct 2019.